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Receptor-mediated transcytosis across the blood–brain barrier (BBB)
may be a useful way to transport therapeutics into the brain. Here
we report that transferrin (Tf)-containing gold nanoparticles can
reach the brain parenchyma from systemic administration in mice
through a receptor-mediated transcytosis pathway. This transport is
aided by tuning the nanoparticle avidity to Tf receptor (TfR),which is
correlated with nanoparticle size and total amount of Tf decorating
the nanoparticle surface. Nanoparticles of both 45 nm and 80 nm
diameter reach the brain parenchyma, and their accumulation there
(visualized by silver enhancement light microscopy in combination
with transmission electron microscopy imaging) is observed to be
dependent on Tf content (avidity); nanoparticleswith large amounts
of Tf remain strongly attached to brain endothelial cells, whereas
those with less Tf are capable of both interacting with TfR on the
luminal side of the BBB and detaching from TfR on the brain side of
the BBB. The requirement of proper avidity for nanoparticles to
reach the brain parenchyma is consistent with recent behavior ob-
served with transcytosing antibodies that bind to TfR.
Effective delivery of therapeutics to the brain has remainedelusive owing to many factors, including inadequate transport
across the blood–brain barrier (BBB). Numerous multidisciplin-
ary-based strategies for transporting therapeutic agents from
the blood into the brain have been proposed (1), including the
use of receptor-mediated transcytosis. Recently, Yu et al. (2)
reported increased accumulation of antibodies to transferrin (Tf)
receptor (TfR) in the brain parenchyma when the antibody af-
ﬁnity was reduced. In that work, antibodies with high TfR afﬁnity
bound strongly to and remained associated with TfRs in the
BBB, whereas antibodies with lower TfR afﬁnity allowed for
their detachment from TfRs and subsequent release into the
brain parenchyma. These results are consistent with a previous
report of a low-afﬁnity (nearly identical to Tf–TfR interaction
strength) antibody that signiﬁcantly accumulated in the brain
parenchyma (3).
Targeted nanoparticles are ﬁnding applications for the de-
livery of a wide variety of therapeutic agents, and several have
already reached the clinical testing stage in humans (4, 5). For
example, in a Phase I clinical trial, a Tf-containing nanoparticle
was used to deliver siRNA to cancer patients and shown to de-
liver functional siRNA to melanoma tumors in a dose-dependent
manner (6). The results demonstrate that Tf-containing nano-
particles can be administered safely to humans.
It is well known that the avidity and receptor selectivity of
targeted nanoparticles can be tuned by the choice of targeting
ligand and its number density; multivalent nanoparticles can en-
gage multiple cell surface receptors simultaneously (7, 8). When
an individual targeting ligand is conjugated to a nanoparticle, the
afﬁnity of the ligand to the receptor is reduced. However, if
the receptor density is such that multiple targeting ligands on the
nanoparticle can bind to the receptors simultaneously, then the
targeted nanoparticle avidity (9) and selectivity (8) can be in-
creased. These effects have been illustrated in several inves-
tigations; for example, Choi et al. (9) reported the interactions of
Tf-containing gold nanoparticles on both cancer cells in vitro and
tumors in vivo in mice. These authors showed that the animal
whole-body biodistribution of Tf-containing gold nanoparticles
of∼70 nm in diameter was independent of the Tf content, but that
the amount of nanoparticles localizing in the cancer cells of solid
tumors at 24 h after injection increased with increasing Tf con-
tent. Thus, the targeting ligand acts as a cell entrance facilitator
rather than altering the biodistribution of the nanoparticles. This
effect is now being reported for different types of targeted
nanoparticles.
The objective of the present study was to investigate whether
the BBB transcytosis behavior of targeted nanoparticles is similar
to the BBB transcytosis behavior of antibodies in the sense that
the avidity must be modulated appropriately to allow receptor
binding from the blood, transcytosis across the BBB, and release
from the receptor into the brain parenchyma. Our expectation
was that the nanoparticles would need proper avidity, size and
surface charge to effectively undergo BBB transcytosis. Our re-
search group has been involved in translating two nanoparticles
from the laboratory into clinical trials. These nanoparticles are
smaller than 100 nm for many reasons, including their ability to
move through tissues. Here we restricted our investigation to
nanoparticles in this size range.
After our experimental studies were completed, another group
reported that nanoparticles in the sub–100-nm range can in fact
move through brain tissue, especially when they have near-neutral
zeta potentials and are coated with a dense polyethylene glycol
(PEG) layer (10). Moreover, nanoparticle zeta potentials that are
slightly negative to near-neutral are desirable, given that highly
negatively and positively charged nanoparticles are known to (i)
disrupt the BBB (11), (ii) facilitate formation of protein coronas
that may mask or alter the function of the targeting ligand (12),
and (iii) illicit unwanted immune responses and more rapid blood
clearance via increased uptake through the mononuclear
phagocyte system (13). Thus, we restricted our nanoparticles to
have near-neutral zeta potentials (<−15 mV, as measured in 1.5
mM KCl).
We found that Tf-containing gold nanoparticles can behave
similarly to antibodies in terms of receptor binding and release at
the BBB. That is, if the avidity of the nanoparticles is too low,
they do not signiﬁcantly bind to TfR from the blood, and if the
avidity is too high, they are less available for release into the
brain parenchyma. Only those nanoparticles with intermediate
avidity are able to effectively transcytose and be released into the
brain parenchyma.
Results
Targeted Nanoparticle Avidity Increases with Tf Amount. Tf-containing
gold nanoparticles were chosen as a model nanoparticle system to
engage the TfR at the BBB. Human Tf has already been used as
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a targeting agent on nanoparticles in human clinical trials (6, 14),
and it is a recognized ligand for the well-established TfR at the
BBB. Human Tf that is fully loaded with iron (holo-Tf) binds
strongly to TfRs (Kd = 1–10 nM) (15), and after vesicle acidiﬁca-
tion and iron release, the subsequent apo-Tf has a reduced binding
strength to TfR (Kd > 700 nM) (15) at physiological pH. Mouse Tf
was not used, for reasons discussed below.
We chose gold nanoparticles for this study owing to their ease of
synthesis, surfacemodiﬁcation through reactions with thiol groups,
quantiﬁcation by inductively coupled plasma–mass spectroscopy
(ICP-MS), and imaging by transmission electron microscopy
(TEM). In addition, gold nanoparticles are convenient for studies
of the BBB because they can be visualized inside and outside the
vasculature by light microscopy through silver enhancement. The
silver enhancement of gold nanoparticles is a highly sensitive
detection technique that has been used to detect zeptomolar con-
centrations of nanoparticles in immune assays (16). Silver en-
hancement also has been used to visualize gold nanoparticles in
kidney and tumor sections through light microscopy (17, 18).
Tf was coupled to gold nanoparticles through an NHS-PEG5k-
OPSS linker, where the N-hydroxysuccinimide (NHS) ester reacts
with Tf through primary amines on lysine groups [the preferred
method of PEG coupling to Tf (19)] and orthopyridyl disulﬁde
(OPSS) reacts with gold surfaces through gold–thiol dative
bonding (Fig. 1). Mono-PEGylated Tf was highly puriﬁed before
coupling to the gold nanoparticles (SI Appendix, Fig. S1), because
di-PEGylated Tf can cause a small degree of particle aggregation.
Gold cores of increasing sizes (5 nm, 20 nm, and 50 nm) were
reacted with increasing amounts of Tf-PEG5k-OPSS, after which
methoxy-PEG5k-thiol (mPEG)-SH (PEGylation) was added to the
nanoparticle surface to increase nanoparticle stability in high ionic
solutions, such as blood. Attempts to use mouse Tf for nano-
particle assembly failed. For unknown reasons, mouse Tf does not
appear to be as stable as human Tf for these types of physical and
chemical manipulations.
Nanoparticle sizes were measured with dynamic light scattering
(DLS) and nanoparticle tracking analysis (NTA) technologies.
NTA methods allow direct visualization of individual nano-
particles and can provide nanoparticle size distributions within
a sample. All NTA sizes listed in Table 1 are from unimodal size
distributions, indicating a single population of similarly sized
nanoparticles. Unfortunately, the smaller-sized nanoparticles can-
not be detected by this method. Given the unimodal NTA size
distributions, DLS was used, with the sizes listed in Table 1. The
nanoparticles measured by both NTA and DLS were essentially
the same size. All of the nanoparticles synthesized had zeta
potentials between −15 mV and −5 mV when measured in
1.5 mM KCl (Table 1). Zeta potential distributions were mea-
sured for the ∼80-nm nanoparticles using NTA methods. The
FWHM values obtained from the zeta potential distributions
did not vary with Tf content. These data are consistent with
a similar Poisson-type distribution of Tf over the nanoparticle
population for each formulation.
Tf content on the nanoparticles was directly measured by (i)
apo-Tf-PEG-OPSS chelation of 64Cu, (ii) nanoparticle formula-
tion with 64Cu-Tf-PEG-OPSS, and (iii) measurement of nano-
particle-associated gamma activity [Cu chelationmethod, modiﬁed
from a previously reported method (20)]. The average Tf content
of some of the nanoparticle formulations are listed in Table 1. The
nanoparticle formulations included a wide range of Tf contents on
the nanoparticle surfaces. Each nanoparticle size had a formula-
tion with very little Tf, as well as a formulation approaching the
maximum number of possible Tf molecules on each particle. The
theoretical maximum density of Tf on the surface of the nano-
particle was estimated based on the total surface area of the par-
ticle (from the surface area of a sphere) and the estimated surface
coverage of each Tf molecule [hydrodynamic radius, ∼4 nm per Tf
(21)]. Note that as the attempted loading of Tf increased (ﬁrst
column of Table 1), the fraction of Tf actually on the nanoparticles
decreased, most likely owing to steric crowding.
More critical than the precise Tf content in each nanoparticle
formulation is nanoparticle avidity and how it changes with Tf
content. Yu et al. (2) performed competitive binding assays with
mouse TfR to provide a relative ranking of the antibodies used in
their study, and Friden et al. (3) used puriﬁed human TfR and
the human K562 cell line to measure Tf and antibody binding.
Here, to provide a relative ranking of nanoparticle avidity, we
obtained binding isotherms using Neuro2A cells as a model cell
type with mouse TfR (SI Appendix, Fig. S2; Kd values listed in
Table 1). We found that Kd value had an inverse relationship
with Tf content (Fig. 2A), and there was a clear increase in
avidity with Tf content for each nanoparticle size tested (Fig.
2B). Within the limited number of nanoparticles used in this
study, we detected an apparent weak effect of size on avidity
(Fig. 2B). Previous studies that included much smaller nano-
particle sizes similarly reported that increasing the size and an-
tibody content of antibody-coated nanoparticles increased the
nanoparticles’ avidity to cell surface receptors (22).
Accumulation of Targeted Nanoparticles in Brain Parenchyma Is
Dependent on Tf Amount. The nanoparticle formulations listed in
Table 1 were administered to mice by lateral tail vein injection.
One mouse each was injected with the formulations of the ∼20-
nm nanoparticles. Based on tissue analyses in these mice, we
decided not to inject additional mice with these formulations,
because the resulting images were conclusively negligible relative
to the images obtained from the ∼45-nm and 80-nm nanoparticle-
treated mice. Three mice each were injected with the 45-nm and
80-nm formulations, and at 8 h postinjection the brains were
resected and processed for silver-enhanced imaging.
Nanoparticles in the parenchyma of each image were quanti-
ﬁed, and the data were compiled into boxplots (Fig. 3A). These
data illustrate how nanoparticle accumulation in the brain pa-
renchyma was affected by both nanoparticle size and Tf content.
Nanoparticles in the 45-nm and 80-nm size range were observed
in the brain parenchyma, and statistically signiﬁcant maximum
levels were obtained with the formulations studied for both sizes.
Neither nanoparticles of ∼20 nm nor formulations with mPEG-
only were clearly seen in the parenchyma.
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Fig. 1. Representation of the targeted nanoparticle assembly process (n ∼120;
PEG molecular mass, 5,000 Da).
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In some regions of a few tissue sections, silver enhancement
deposited in patterns that we classiﬁed as not speciﬁc to nano-
particles. Moreover, several areas with silver enhancement char-
acteristic of nanoparticles were classiﬁed as not related to
receptor- mediated transcytosis (SI Appendix, Fig. S3). We docu-
mented these events, but did not include them in our quantitative
analysis. One brain from a mouse not injected with nanoparticles
was stained with hematoxylin and silver enhancement solution,
and some background signal due to silver enhancement was
detected (SI Appendix, Fig. S4). These nonspeciﬁc events related
to silver enhancement are clearly distinguishable from signals in
the parenchyma due to gold nanoparticles.
Fig. 4 presents representative images from some of the for-
mulations studied. Full, unmagniﬁed images are provided in SI
Appendix, Figs. S5–S7. Vessel staining is clearest in the images
of the ∼20-nm nanoparticles that remained largely in the vas-
culature (vessels stained black, with a lack of clearly visible
nanoparticles outside the vasculature). The images of the 45-nm,
30-Tf and 80-nm, 20-Tf formulations are representative of the
majority of images obtained with clear nanoparticle signal in the
parenchyma. The arrow in the 80-nm, 200-Tf image points to
a nanoparticle that is out of focus. Within the 5-μm tissue sec-
tions, it was impossible to consistently obtain images in which all
nanoparticles were in focus. These out-of-focus nanoparticles
were also included in the quantitative analysis.
High Tf Content Nanoparticles Have Increased Association with
Brain Endothelial Cells. High binding avidity with high nanoparticle
Tf content reduced the parenchymal accumulation of the 45-nm
and 80-nm nanoparticles (Table 1 and Figs. 2, 3, and 4). Addition-
ally, high-avidity 80-nm nanoparticles (with 200 Tf) were consis-
tently associated with the blood vessels to a greater degree than the
untargeted 80-nm nanoparticles. To quantify this phenomenon, at
8 h postinjection we homogenized two brains containing mPEG-
only nanoparticles and three brains each of the 80-nm nano-
particles containing 20 Tf and 200 Tf, and measured the total brain
gold content by ICP-MS (Fig. 3C). The 80-nm nanoparticle silver
enhancement signal appeared to be discrete in the blood vessels
(unlike the continuous signal of the 20-nm and 45-nm nano-
particles in the vessels). We quantiﬁed this vessel-associated
nanoparticle signal for each 80-nm formulation (Fig. 3B).
Consistent with the vessel-associated nanoparticle content
quantiﬁed from the images, more gold was detected in the bulk
brain (vessels and parenchyma) with higher nanoparticle Tf
content by ICP-MS. The combined vessel analysis, ICP-MS
analysis, and parenchymal quantitative imaging analysis found
that more 80-nm nanoparticles remained in the bulk of the brain
with increasing Tf, not because they entered the brain paren-
chyma, but because they were largely stuck in or on the endo-
thelial cells of the vasculature.
TEM Images Show That Nanoparticles Undergo Receptor-Mediated
Transcytosis and Are Present in Brain Parenchyma. Because the 80-
nm nanoparticle formulations showed the greatest accumulation
in the brains, we subjected these nanoparticles to additional
TEM analysis (Fig. 5). All sample images were obtained from the
cerebral cortex. No untargeted 80-nm nanoparticles were found
in the endothelial cells or brain parenchyma after several hours
of imaging, although they were detected in the vessel lumen,
consistent with the light microscopy data. Nanoparticles with low
(20 Tf/nanoparticle) and high (200 Tf/nanoparticle) Tf content
were observed in endothelial cells, as well as in the parenchyma
(Fig. 5 A–D). Nanoparticles were detected inside endothelial cell
vesicles (e.g., Fig. 5B), suggesting a transcellular route of delivery
to the brain parenchyma. Untargeted nanoparticles were not
observed inside endothelial cells, and all 80-nm formulations had
similar zeta potentials, suggesting that the Tf-coated nano-
particles entered into the endothelial cells via a TfR-mediated
process. The reduced quality of tissue microstructures in these
images can be attributed to the tissue processing to allow de-
tection of extracellular nanoparticles (CO2 asphyxiation followed
by brain resection and immediate submersion in formalin solu-
tion). Higher-quality cellular microstructures are preserved with
a perfusion ﬁxation technique (Fig. 5 E–I).
Nanoparticle-associated toxicity has been suggested to degrade
the BBB (11), which may be a factor contributing to nanoparticle
access to the brain parenchyma. Cardiac perfusion-ﬁxation with
a solution of ﬁxative containing the BBB-impermeable TEM
contrast agent lanthanum nitrate has been previously used to en-
sure BBB integrity (23). Each 80-nm nanoparticle formulation was
injected, and cardiac-perfusion ﬁxation was performed at 8 h post-
injection. In all three brains, lanthanum remained exclusively
within the vasculature (strongly staining glycocalyx on the surface
Table 1. Nanoparticle formulations and characterizations
Formulations
(core + Tf)
Tf from 64Cu
experiment
Nanoparticle
diameter, DLS, nm
Nanoparticle
diameter, NTA, nm
Zeta potential
in KCl, mV Kd, nM
5 nm + mPEG 0 21.6 ± 0.2 ND −11.4 ± 1.3 —
5 nm + 3 Tf 3.2 21.0 ± 2.5 ND −12.9 ± 0.3 4.9
5 nm + 6 Tf 4.6 25.3 ± 2.5 ND −10.0 ± 1.9 3.1
20 nm + mPEG 0 46.1 ± 2.7 ND −8.3 ± 0.8 —
20 nm + 10 Tf 7.4 44.6 ± 3.2 ND −14.4 ± 2.2 1.7
20 nm + 20 Tf 9.5 43.6 ± 4.6 ND −6.8 ± 0.4 1.5
20 nm + 30 Tf ND 48.3 ± 2.9 ND −14.1 ± 1.4 0.71
20 nm + 100 Tf 49.9 46.3 ± 1.3 ND −10.2 ± 2.3 0.018
50 nm + mPEG 0 78.8 ± 3.1 72.0 ± 1.7 −5.7 ± 1.1 —
50 nm + 20 Tf ND 78.1 ± 2.8 69.7 ± 2.3 −5.3 ± 2.0 0.89
50 nm + 200 Tf 107.3 85.4 ± 2.9 73.3 ± 2.1 −6.3 ± 0.4 0.014
ND, not determined. All reported errors are SDs calculated from three measurements on the same sample.
Fig. 2. Binding data of gold nanoparticle formulations on Neuro2A cells.
(A) Effects of nanoparticle Tf content on Kd of the nanoparticle to Neuro2A
TfRs. (B) Effects of nanoparticle size and Tf content on Kd of the nanoparticle
to Neuro2A TfRs.
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of the endothelial cells with partial interendothelial cleft stain-
ing), and no subendothelial staining was seen (e.g., Fig. 5 F and
G). In addition, no nanoparticles were observed in the lumen of the
vessels after vascular perfusion, although Tf-coated nanoparticles
were again localized in the endothelial cells and parenchyma (Fig. 5
H and I). Thus, the BBB remained intact and was not per-
meabilized to large ions after exposure to the 80-nm gold nano-
particle formulations. An intact BBB that allows only Tf-associated
nanoparticles to reach the parenchyma demonstrates that the Tf-
targeted nanoparticles reach the brain through a receptor-medi-
ated transcytosis pathway.
Discussion
PEGylated nanoparticles in the sub–100-nm diameter size range
are known to be able to move through brain tissue (10), and our
ﬁndings show that sub–100-nm nanoparticles that have near-
neutral zeta potentials and contain a PEG coating with protein
ligands can spread through the brain tissue. Thus, if these nano-
particles can transcytose across the intact BBB, they may be useful
for delivering a broad spectrum of therapeutic and imaging
agents. Of major importance is the ﬁnding that the nanoparticles
do reach the brain parenchyma, and that they do so without
damaging the BBB. Motivated by the results of Yu et al. (2), and
by the fact that the avidity of nanoparticles can be altered by
targeting ligand choice and number density, we prepared a series
of targeted nanoparticles with a range of avidities for TfR. As-
sessment of avidity for TfR on Neuro2A cells showed that avidity
was affected by both nanoparticle size and the total number of Tf
molecules decorated on the nanoparticle surface. We investigated
this set of targeted nanoparticles for their ability to interact with
and transcytose across the BBB in mice. Our results show that
nanoparticle avidity plays a signiﬁcant role in the transcytosis be-
havior. Nanoparticles with the highest avidities were bound to the
BBB, but demonstrated reduced accumulation in the brain pa-
renchyma relative to nanoparticles with reduced avidity.When the
avidity was too low, nanoparticles did not engage the BBB.
The need for a speciﬁc avidity to allow transcytosis of targeted
nanoparticles is consistent with behavior observed in trans-
cytosing antibodies to TfR (2). Nanoparticles with high avidity
can have similar Kd values as typical antibodies, and much like
high-afﬁnity antibodies, these nanoparticles engage the BBB but
do not enter the brain parenchyma in appreciable amounts.
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Fig. 3. Quantitative studies of gold nanoparticles in the brain. (A) Quanti-
tation of the nanoparticles observed in the brain parenchyma by silver en-
hancement after tail vein injection (n = 3 for 45-nm and 80-nm formulations;
n = 1 for 20-nm formulations). (B) Quantitation of 80-nm formulations in the
blood vessels by silver enhancement. P values of A and B were calculated
from nonnormal distributions using the Mann–Whitney U test (Wilcoxon
rank-sum test) of compiled data from all mice investigated in each nano-
particle formulation. (C) ICP-MS data of bulk brain gold content from the 80-
nm formulations. mPEG: n = 2; 20 Tf and 200 Tf: n = 3. Error bars indicate SE.
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Fig. 4. Sample images from hematoxylin-stained and silver-enhanced brain sections. Shown are images from a range of nanoparticle formulations injected
systemically with brains resected and processed 8 h later. Black arrows accentuate clearly visible nanoparticles. (Left) 20-nm nanoparticles with 6 Tf, 3 Tf, and
0 Tf (from top to bottom). (Center) 45-nm nanoparticles with 100 Tf, 30 Tf, and 10 Tf. (Right) 80-nm nanoparticles with 200 Tf, 20 Tf, and 0 Tf.
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Nanoparticles of lesser avidity were able to reach the brain pa-
renchyma, most likely owing to the release of the nanoparticles on
transcytosis. When the avidity was too low, nanoparticles in cir-
culation did not engage TfRs on the BBB, probably because they
were outcompeted by the inherent mouse Tf in blood for the
available TfRs. These results show that targeted nanoparticles can
be prepared and their avidity tuned to allow for transcytosis
across the BBB. The avidity, along with nanoparticle size and
surface charge, need to be controlled to allow the transcytosis
of intact nanoparticles across the BBB without changing the
properties of the BBB. We are exploring these nanoparticle
design rules in an effort to prepare targeted nanoparticles with
therapeutic agents.
Materials and Methods
Complete details of thematerials andmethods used in this study are provided
in SI Appendix.
Tf-PEG-OPSS Synthesis. Human holo-Tf was reacted with NHS-PEG-OPSS to
form Tf-PEG-OPSS. A pure monoPEGylated fraction of Tf was obtained after
HPLC separation, followed by hydrophobic interaction chromatography
separation. After the separation steps, Tf was reloaded with iron via in-
cubation in iron citrate with 100 mM sodium bicarbonate.
Au-PEG-Tf Synthesis. Gold nanoparticles of increasing size (5 nm, 20 nm, and
50 nm) were stirred with the appropriate molar excess of Tf-PEG-OPSS (e.g.,
10 mol excess Tf added to gold for a 10-Tf/particle formulation) for 90 min,
followed by the addition of an excess amount of mPEG-SH for an additional
90 min. The gold particles were pelleted by centrifugation, and unbound
PEG was removed with the supernatant. The particles were resuspended
in water and then sonicated for 10 min. The washing procedure was
repeated twice.
DLS. Particle sizes and zeta potentials were measured with a Brookhaven
Instruments ZetaPALS. Reported values were averaged from three runs at
a target residual of 0.02. Measurements are reported as average ± 1 SD.
NTA. NTA measurements were performed with a NanoSight NS500 in-
strument. The data are reported as themode of the size distributionwith 1 SD
of three runs on the same sample.
Nanoparticle Cell Binding Assay. Fixed Neuro2A cells in suspension were in-
cubated with increasing concentrations of gold nanoparticles for 90 min, with
mixing every 15 min to avoid settling. The cells were then washed three times
with PBS to remove unbound gold, treated with silver enhancement solution,
and assessed for gold content in a 96-well plate reader (Tecan Inﬁnite M200;
excitation, 310 nm; emission, 400 nm). The data wereﬁt to a Langmuir binding
isotherm, with Bmax and Kd ﬁt nonlinearly with MATLAB nlinﬁt (MathWorks).
Nanoparticle Tf Content. apo-Tf-PEG-OPSS was incubated with 4 mCi of 64Cu
in 50 mM bicarbonate for 90 min. Unbound 64Cu was separated from Tf-
PEG-OPSS with a Micro Bio-Spin column (Bio-Rad). After formulation of the
gold nanoparticles with 64Cu-Tf-PEG-OPSS, the nanoparticles were pelleted
by centrifugation, and unbound 64Cu-Tf-PEG-OPSS was removed with the
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Fig. 5. TEM images of gold nanoparticles in the brain. Mi, mitochondria; Lu, lumen; En, endothelial cell; Pa, parenchyma; EC, endothelial cleft; NP, nano-
particle; Gly, glycocalyx. (A) 80- nm, 20-Tf nanoparticle in the parenchyma. (B) 80-nm, 20-Tf nanoparticle inside a vesicle of a BBB endothelial cell. (C) 80-nm,
200-Tf nanoparticles in the parenchyma. (D) 80-nm, 200-Tf nanoparticle near the basal surface of an endothelial cell. (E) Perfusion ﬁxation with lanthanum
nitrate showing lanthanum penetrating the interendothelial cleft with no subendothelial staining. (F and G) Injection of 80-nm particles, followed by per-
fusion ﬁxation at 8 h postinjection. Neither the 20-Tf/Au formulation (F) nor the 200-Tf/Au formulation (G) degrades the BBB tight junctions to lanthanum
nitrate; the same interendothelial cleft penetration with no subendothelial staining is seen. (H) 80-nm, 200-Tf particle inside and near the apical surface of the
endothelial cell. (Note that the lanthanum nitrate-stained glycocalyx separated from the cell surface owing to the electron beam during imaging.) (I) 80-nm,
200-Tf particle found within the brain parenchyma after perfusion ﬁxation.
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supernatant. The nanoparticles were sonicated and washed with 1.5 mL of
water. Gamma activities of each particle formulation were counted with
a Wizard gamma counter (PerkinElmer), and a standard curve was used to
determine the Tf content of the nanoparticle population.
Animal Studies. Female BALB/c mice (Jackson Laboratory) received i.v. doses of
nanoparticles in 150 μL of PBS through the lateral tail vein. Injected doses were
as follows: 20-nm gold, 5 × 1013 nanoparticles/mouse; 45-nm gold, 2.9 × 1012
nanoparticles/mouse; 80-nm gold, 4.5 × 1011 nanoparticles/mouse. At 8 h
postinjection, the brains were resected and placed in 4% paraformaldehyde
for further analysis. For TEM perfusion ﬁxation analysis, the right atrium was
clipped, and the left ventricle was perfused with 10% sucrose, followed by the
ﬁxative (4% paraformaldehyde, 0.05% glutaraldehyde, and 5% lanthanum
nitrate in 100 mM sodium cacodylate buffer; pH 7.2). After perfusion, the
brains were resected and placed in 4% paraformaldehyde for further analysis.
TEM. Osmium-stained and epoxy-embedded brains were sectioned, further
stainedwith uranyl acetate and lead citrate, and imagedwith a 80-kV Technai
TF30UT transmission electron microscope (FEI).
Light Microscopy. Parafﬁn-embedded brains were sectioned, deparafﬁnized,
and treatedwith silver enhancement solution (Ted Pella). Tissue sections were
counterstainedwith hematoxylin and imagedon anOlympus IX50microscope
with a 40× objective using QCapture Pro imaging software (QImaging).
Image Analysis, Particle Counting, and Statistics. A total of 40 images were
obtainedofeachtissuesection,with imagesthroughoutfourregionsofthebrain
(10 images per region): rostral, dorsal, and ventral regions, and cerebellum.
Nanoparticles visualized in the parenchyma and 80-nm nanoparticles visualized
in the vessels were manually counted, and the data were binned in MATLAB.
Pairwise comparisongroups (e.g., 80nm20Tfvs. 80nm200Tf)of thenonnormal
distributions were analyzed for statistically signiﬁcant differences using the
Mann–Whitney U test (Wilcoxon rank-sum test) and P values reported in Fig. 3.
ICP-MS. Brains were microwaved in aqua regia (70% HNO3 and 30% HCl in
a 3:1 volume ratio) until they were fully homogenized. After 20.5 mL of
deionized water was added, the sample was centrifuged at 3,200 × g for 15
min to remove cell debris. The supernatant was analyzed for gold content
with an Agilent HP 4500 ICP-MS system. Reported values are expressed as
percentage of injected dose per gram of brain tissue. Error bars represent
the SE from the measurements obtained from each group of mice.
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